Vatera Healthcare Partners

ImmusanT is a biotechnology company that develops diagnostics and therapeutics for the diagnosis and treatment of celiac disease. The company focuses on restoring tolerance to gluten in celiac disease by harnessing new discoveries in immunology that improve diagnosis and treatment. It develops Nexvax2, a therapeutic vaccine for treating, preventing, and diagnosing celiac disease. The company also develops a functional T-cell test to diagnose and monitor the maintenance of immune tolerance with peptide based therapy. ImmusanT was incorporated in 2010 and is based in Cambridge, Massachusetts.

Melinta Therapeutics is an antibiotics-focused company. The company’s mission is to discover, develop and commercialize urgently needed, groundbreaking antibiotics to overcome drug-resistant, life-threatening infections. The need for new therapies for drug-resistant infections is widely recognized as one of the most serious public health issues facing the world today. To meet this need, Melinta Therapeutics is rapidly progressing its late-stage investigational antibiotic, delafloxacin, which is currently in Phase 3 development for acute bacterial skin and skin structure infections (ABSSSI). In addition, Melinta is focused on its ongoing research program to develop a new class of antibiotics designed to overcome the resistant ESKAPE pathogens known to cause the majority of serious hospital infections and patient deaths. Melinta Therapeutics is privately held and backed by Vatera Healthcare Partners and Warburg Pincus.

ImmusanT is a biotechnology company that develops diagnostics and therapeutics for the diagnosis and treatment of celiac disease. The company focuses on restoring tolerance to gluten in celiac disease by harnessing new discoveries in immunology that improve diagnosis and treatment. It develops Nexvax2, a therapeutic vaccine for treating, preventing, and diagnosing celiac disease. The company also develops a functional T-cell test to diagnose and monitor the maintenance of immune tolerance with peptide based therapy. ImmusanT was incorporated in 2010 and is based in Cambridge, Massachusetts.

Melinta Therapeutics is an antibiotics-focused company. The company’s mission is to discover, develop and commercialize urgently needed, groundbreaking antibiotics to overcome drug-resistant, life-threatening infections. The need for new therapies for drug-resistant infections is widely recognized as one of the most serious public health issues facing the world today. To meet this need, Melinta Therapeutics is rapidly progressing its late-stage investigational antibiotic, delafloxacin, which is currently in Phase 3 development for acute bacterial skin and skin structure infections (ABSSSI). In addition, Melinta is focused on its ongoing research program to develop a new class of antibiotics designed to overcome the resistant ESKAPE pathogens known to cause the majority of serious hospital infections and patient deaths. Melinta Therapeutics is privately held and backed by Vatera Healthcare Partners and Warburg Pincus.

Pearl Therapeutics is developing unique dual and triple combination products for the treatment of widely prevalent respiratory diseases, including chronic obstructive pulmonary disease. Pearl's current focus is on making advanced inhaled therapies available to broad patient populations via familiar and accepted metered dose inhalers. Pearl is a privately held company led by a seasoned team of respiratory product development experts. Pearl aims to offer patients and healthcare providers alternatives that better meet their needs and improve upon the safety and efficacy of existing respiratory therapeutics to achieve better clinical outcomes.

Melinta Therapeutics is an antibiotics-focused company. The company’s mission is to discover, develop and commercialize urgently needed, groundbreaking antibiotics to overcome drug-resistant, life-threatening infections. The need for new therapies for drug-resistant infections is widely recognized as one of the most serious public health issues facing the world today. To meet this need, Melinta Therapeutics is rapidly progressing its late-stage investigational antibiotic, delafloxacin, which is currently in Phase 3 development for acute bacterial skin and skin structure infections (ABSSSI). In addition, Melinta is focused on its ongoing research program to develop a new class of antibiotics designed to overcome the resistant ESKAPE pathogens known to cause the majority of serious hospital infections and patient deaths. Melinta Therapeutics is privately held and backed by Vatera Healthcare Partners and Warburg Pincus.

Pearl Therapeutics is developing unique dual and triple combination products for the treatment of widely prevalent respiratory diseases, including chronic obstructive pulmonary disease. Pearl's current focus is on making advanced inhaled therapies available to broad patient populations via familiar and accepted metered dose inhalers. Pearl is a privately held company led by a seasoned team of respiratory product development experts. Pearl aims to offer patients and healthcare providers alternatives that better meet their needs and improve upon the safety and efficacy of existing respiratory therapeutics to achieve better clinical outcomes.

Pearl Therapeutics is developing unique dual and triple combination products for the treatment of widely prevalent respiratory diseases, including chronic obstructive pulmonary disease. Pearl's current focus is on making advanced inhaled therapies available to broad patient populations via familiar and accepted metered dose inhalers. Pearl is a privately held company led by a seasoned team of respiratory product development experts. Pearl aims to offer patients and healthcare providers alternatives that better meet their needs and improve upon the safety and efficacy of existing respiratory therapeutics to achieve better clinical outcomes.

ImmusanT is a biotechnology company that develops diagnostics and therapeutics for the diagnosis and treatment of celiac disease. The company focuses on restoring tolerance to gluten in celiac disease by harnessing new discoveries in immunology that improve diagnosis and treatment. It develops Nexvax2, a therapeutic vaccine for treating, preventing, and diagnosing celiac disease. The company also develops a functional T-cell test to diagnose and monitor the maintenance of immune tolerance with peptide based therapy. ImmusanT was incorporated in 2010 and is based in Cambridge, Massachusetts.

Pearl Therapeutics is developing unique dual and triple combination products for the treatment of widely prevalent respiratory diseases, including chronic obstructive pulmonary disease. Pearl's current focus is on making advanced inhaled therapies available to broad patient populations via familiar and accepted metered dose inhalers. Pearl is a privately held company led by a seasoned team of respiratory product development experts. Pearl aims to offer patients and healthcare providers alternatives that better meet their needs and improve upon the safety and efficacy of existing respiratory therapeutics to achieve better clinical outcomes.